Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes
Main finding · Death or MIResult — go to the resultAdjusted hazard ratio 0.86 95% CI 0.62–1.17Authors' conclusion
Ticagrelor and prasugrel are increasingly used in patients with CCS undergoing PCI with similar 1-year efficacy and safety when compared to clopidogrel.
Study context
- Population
- Consecutive patients undergoing percutaneous coronary intervention (PCI) for chronic coronary syndromes at a tertiary centre, 2014–2019
- Participants
- 11,508 patients
- Exposure
- Ticagrelor/prasugrel vs clopidogrel after PCI for chronic coronary syndromes (CCS)
- Ticagrelor/prasugreln = 2,860
- Clopidogreln = 8,648reference
- Outcome
- Composite of:
- Death
- MI
- Follow-up
- 1 year
Methodological detailssingle-centre, consecutive patients, propensity score stratification
- Single-centre
- Consecutive patients
- Propensity score stratification
Main finding
Death or MI
Adjusted hazard ratio
0.86
95% CI 0.62–1.17
P = 0.33
By group
Ticagrelor/prasugrelvs Clopidogrel
adjusted HR 0.86 (95% CI 0.62–1.17); P = 0.33
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Death or myocardial infarction (MI) across subgroups, incl. complex PCI
- No difference in primary outcome across subgroups, including complex PCI
Safety
| Outcome | Adjusted HR (95% CI) | P value | |
|---|---|---|---|
| Bleeding · 1 yearPropensity score stratification | 0.75 (0.46–1.21) | P = 0.23 | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes. EuroIntervention. Published 20 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →